<DOC>
	<DOCNO>NCT00231595</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy three dos topiramate ( 50 milligram [ mg ] , 100mg , 200mg per day ) compare placebo prevention migraine . The study also assess dose response relationship efficacy treatment topiramate versus placebo Health-Related Quality Life .</brief_summary>
	<brief_title>A Study Efficacy Safety Topiramate Prevention Migraine</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group , multi-center study evaluate efficacy safety three different dos topiramate ( 50mg , 100mg , 200mg daily ) migraine prophylaxis . The study consist five phase : Baseline ( determination whether patient meet eligibility criterion taper migraine medication patient already take ) , Double-Blind ( patient receive either 50 milligram [ mg ] , 100mg , 200mg topiramate , placebo ) , Blinded Transition Phase ( dos study medication adjust 7 week preparation Open-Label Extension Phase ) , Open-Label Extension Phase ( patient continue study medication open-label manner 6 month ; dos adjust maximize effectiveness minimize side effect ) , Taper/Exit Phase ( study medication slowly discontinue 2 week ) . The primary study hypothesis one three dos topiramate ( 50 , 100 , 200 mg/day ) superior placebo prophylaxis migraine base change monthly ( 28 day ) migraine period rate Prospective Baseline Period Double-Blind Phase . Topiramate tablet ( 50milligrams [ mg ] , 100mg , 200mg , placebo ) take mouth twice-daily regimen 26-week Double-Blind Phase . Doses adjust continue 6 month Open-Label Extension Phase taper 2 week .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Medical history consistent migraine without aura accord International Headache Society ( IHS ) least 6 month prior study Between 3 12 migraine period great 15 headache day ( migraine nonmigraine ) per month Baseline Phase No clinically significant abnormality neurological exam , electrocardiogram ( ECG ) clinical laboratory test result baseline Female patient must postmenopausal least 1 year , surgically incapable childbearing , practice abstinence , practice acceptable method contraception ( require negative pregnancy test ) Patients headache migraine Patients episodic tension sinus headache Onset migraine age 50 year Patients fail two adequate regimen migraine prophylaxis Patients overuse pain medication certain medication</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Common Migraine</keyword>
	<keyword>Classic Migraine</keyword>
	<keyword>Headache</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Prevention</keyword>
</DOC>